Treatment of severe proliferative lupus nephritis: the current state
Open Access
- 1 September 2003
- journal article
- review article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 62 (9) , 799-804
- https://doi.org/10.1136/ard.62.9.799
Abstract
Despite the development of new modalities, cyclophosphamide (CYC) remains the preferred initial treatment for severe proliferative lupus nephritis. Controversies continue about the best route, dosage, and duration of CYC treatment. For recalcitrant disease, new immunosuppressive and immunomodulating agents, immunoablative high dose CYC, nucleoside analogues, apheresis, and the biological response modifiers can be considered.Keywords
This publication has 84 references indexed in Scilit:
- Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti‐CD154: A randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002
- Advances in the Treatment of Lupus NephritisAnnual Review of Medicine, 2001
- Immunoadsorption onto protein A induces remission in severe systemic lupus erythematosusNephrology Dialysis Transplantation, 2000
- Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamideKidney International, 2000
- Lupus nephritis in southern Chinese patients: Clinicopathologic findings and long-term outcomeAmerican Journal of Kidney Diseases, 1999
- Treatment‐free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamideArthritis & Rheumatism, 1994
- Treatment of Murine Lupus with CTLA4IgScience, 1994
- Therapy of Lupus NephritisNew England Journal of Medicine, 1986
- Evidence for the Superiority of Immunosuppressive Drugs and Prednisone over Prednisone Alone in Lupus NephritisNew England Journal of Medicine, 1984
- Treatment of Diffuse Proliferative Lupus Nephritis with Prednisone and Combined Prednisone and CyclophosphamideNew England Journal of Medicine, 1978